KPV Peptide

Quick Summary

What it is. KPV is a tripeptide consisting of three amino acids — lysine, proline, and valine — corresponding to the final three amino acids of the larger peptide alpha-melanocyte-stimulating hormone (α-MSH).

Most-studied uses. Anti-inflammatory action in gastrointestinal conditions (particularly ulcerative colitis and Crohn’s disease research models), atopic dermatitis and skin inflammation.

Current U.S. legal status (April 2026). Removed from FDA Category 2 on April 15, 2026. Pending final 503A Bulks List placement at the July 23–24, 2026 PCAC meeting. Legal via prescription through a licensed compounding pharmacy.

Expected post-PCAC price. $80–$180 for a 30-day oral capsule supply.

Evidence base. Preclinical research is substantial for GI indications. Some early-phase human clinical data exists — more than most peptides on this list. Clinical application is emerging.

What is KPV?

KPV — lysine-proline-valine — is the C-terminal tripeptide of α-MSH (alpha-melanocyte-stimulating hormone), a longer peptide best known for its role in pigmentation and immune modulation. The KPV fragment retains much of α-MSH’s anti-inflammatory activity without the pigmentary effects of the parent molecule, which is part of why it has drawn research attention for inflammatory conditions.

The mechanism proposed in the literature involves modulation of pro-inflammatory signaling pathways, including reduced activation of NF-κB and downstream inflammatory cytokines. The effect appears to be local and tissue-targeted, which is relevant to its GI and dermatologic applications.

What the Research Shows

Gastrointestinal inflammation — the strongest evidence

KPV is unusual among peptides on the April 15 list because it has been studied in relatively more mature clinical research for GI indications:

• Dextran sulfate sodium (DSS) colitis models in mice — KPV administration reduces colitis severity, inflammation markers, and mucosal damage, with particularly strong results when delivered orally or rectally (targeting local colonic tissue).
• Interleukin-10 deficient mouse models of chronic colitis — KPV administration reduces inflammation.
• Early human work — small clinical studies of KPV in ulcerative colitis patients have shown preliminary signals consistent with the preclinical findings, though sample sizes remain small.

Skin and inflammatory dermatologic conditions

KPV has been studied in atopic dermatitis models and in early topical formulations for inflammatory skin conditions. The underlying mechanism overlaps with the GI work — reduction of local inflammatory cytokine signaling.

What’s less clear

KPV has been discussed in broader immune and longevity contexts. The evidence for these applications is substantially weaker than for the GI and dermatologic indications. If you encounter marketing positioning KPV as a general “immune peptide” or “longevity peptide,” treat that as overreach relative to the literature.

Legal and Regulatory Status

April 15, 2026 reclassification

KPV was among the 12 peptides removed from FDA Category 2 on April 15, 2026.

July PCAC outlook

KPV’s clinical use case is relatively narrow (GI-inflammatory and dermatologic), but its evidence base within those indications is better-developed than most of its peer peptides. This could cut two ways: a clean approval path (the narrow, well-characterized use case is the kind of profile PCAC tends to approve without friction), or a restricted approval path (PCAC may approve KPV specifically for GI and dermatologic indications rather than broad compounding latitude, which some practitioners consider a strict-but-defensible outcome).

Either way, access is expected to improve materially by Q4 2026. We’ll update this page within 72 hours of the PCAC outcome.

State-level variance

See the state-by-state tracker for your jurisdiction’s specific pharmacy compounding rules.

How It’s Typically Administered

Informational only; dosing is prescriber-determined.

KPV’s administration routes are notably different from most peptides on the April 15 list. Oral capsules are the most common format for GI indications. Rectal suppositories are used for targeted colonic delivery in distal ulcerative colitis cases. Topical formulations are used for dermatologic indications. Subcutaneous injection is less common; used in some practitioner protocols.

The GI-targeted delivery is part of why KPV has a distinct profile from the injectable-focused peptides on the list.

Reported Safety Signals

The available literature — both preclinical and the limited human data — reports KPV as well-tolerated. Adverse events in human studies have been infrequent and mild. Because the tripeptide is short and closely resembles a fragment of a naturally occurring human peptide, its safety profile tends to look favorable relative to larger synthetic constructs.

As with all peptides on the April 15 list, long-term human safety data is limited, and supervised use by a licensed clinician is the standard.

Expected Pricing (Post-PCAC)

Format	Expected price range
Oral capsules (30-day supply)	$80–$180
Rectal suppositories	$100–$220
Topical formulation	$60–$140
Subcutaneous injection (5mg vial)	$120–$220

KPV has historically been less expensive than larger peptides like BPC-157 and TB-500 because its synthesis is simpler. Post-PCAC retail pricing should reflect this.

How to Source It Legitimately

Same framework as the rest of the April 15 peptides: prescriber → compounding pharmacy → COA-verified batch → supervision. Apply the 10-point pharmacy checklist.

A practical note for KPV specifically: for GI indications, your prescriber may well be a gastroenterologist or primary care clinician rather than a “peptide-focused” prescriber. That is a perfectly reasonable sourcing path and often more clinically sound than routing through a peptide-specialist telehealth brand.

Common Questions

Is KPV the same as alpha-MSH?

No. KPV is a fragment of α-MSH — specifically, the final three amino acids. It retains the anti-inflammatory activity but not the pigmentary activity of the parent peptide.

Is KPV legal in 2026?

Post-April 15, 2026, KPV is legally compoundable under prescription through a licensed compounding pharmacy, pending final 503A Bulks List placement in July.

Can KPV replace my ulcerative colitis medication?

No, and we would be surprised by any legitimate prescriber who framed it that way. KPV is being studied as an adjunct to standard-of-care therapy for inflammatory GI conditions, not a replacement. Work with your gastroenterologist.

Is KPV safe?

Reported short-term safety is favorable across the available research, which is more mature than most peptides on the April 15 list. Long-term human data remains limited.

How long does KPV take to work?

Practitioner and patient reports for GI indications describe onset over 2–4 weeks, with meaningful symptom improvement emerging over 6–8 weeks of consistent use.

Is oral KPV effective, or do I need injections?

Oral KPV is the most commonly prescribed format for GI indications, and preclinical evidence supports oral activity for colonic inflammation. Injectable use is less common and typically reserved for specific clinical contexts.

What’s the difference between KPV and BPC-157 for gut issues?

They are distinct mechanisms with overlapping indications. BPC-157 is thought to support mucosal healing broadly; KPV more specifically modulates the inflammatory cascade. Some practitioners prescribe them together; many use one or the other based on clinical picture. This is a prescriber call.

Related Compounds

• BPC-157 — Alternative or complementary for GI and mucosal healing. �����������������